Relative efficacy of two acellular pertussis vaccines during three years of passive surveillance.
Prolonged unblinded passive surveillance of the trial cohort from the Swedish 1986-87 pertussis vaccine efficacy trial indicates that a two-component vaccine, containing pertussis toxoid and filamentous haemagglutinin, provided better long-term protection against pertussis than a monocomponent pertussis toxoid vaccine. The relative risk (RR) for culture-confirmed pertussis was 1.5 (95% confidence interval (CI) 1.0-2.4), and RR for pertussis according to parents' diagnoses was also 1.5 (95% CI 1.1-2.1), for the monocomponent vaccine compared with the two-component vaccine.
Storsaeter
J
J
Department of Paediatrics, Sachs' Children's Hospital, Karolinska Institute, Stockholm, Sweden.
Olin
P
P
D005260:Female; D006801:Humans; D015994:Incidence; D007223:Infant; D008297:Male; D010567:Pertussis Vaccine / Q000627:therapeutic use*; D013997:Time Factors; D014917:Whooping Cough / Q000453:epidemiology / Q000517:prevention & control*
D010567:Pertussis Vaccine